Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + vincristine + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**DOC** is a multi-agent chemotherapy reduction regimen comprising **dexamethasone, vincristine, and cyclophosphamide**. In the New York Medical College RADICAL pediatric lymphoma protocol, it is used as initial cytoreductive therapy before response assessment and subsequent risk-adapted treatment. Dexamethasone activates glucocorticoid receptor-mediated transcriptional programs and promotes lymphoid-cell apoptosis; vincristine disrupts mitotic spindle function by inhibiting microtubule dynamics; and cyclophosphamide is a DNA-alkylating prodrug that produces cytotoxic DNA crosslinks. The regimen is being evaluated within a Phase 2 targeted-immunotherapy strategy intended to reduce cumulative anthracycline exposure while preserving lymphoma control in children, adolescents, and young adults.
- Other names
- dexamethasone + vincristine + cyclophosphamideDOCDOC reduction therapyDOC regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on dexamethasone + vincristine + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + vincristine + cyclophosphamide.